 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
CELLEGY PHARM INC, (CLGY) Stock Rating Learn More
| Our Overall Rating on CELLEGY PHARM INC, CLGY is Not Available | | Cellegy Pharmaceuticals, Inc., a development stage specialty biopharmaceutical company, engages in the development and commercialization of prescription drugs for womens health care. Its products are used for HIV prevention and sexual dysfunction, as well as gastrointestinal disorders and certain cancers. The company products include Rectogesic nitroglycerin ointment for the treatment of anal fissures, as well as skin care blends, including skin moisturizers. Its products in clinical trials include Cellegesic, a nitroglycerin ointment used for the treatment of chronic anal fissures, with the potential for broader use in hemorrhoids and dyspareunia pain-related female sexual dysfunction; Savvy is a contraceptive vaginal gel for women, designed to prevent HIV/AIDS; Fortigel, a testosterone replacement therapy for male hypogonadism; and Tostrelle, a testosterone gel for female hormone replacement therapy. The company sells its products to physician specialists, including Gastroenterologists and Obstetrician-Gynecologists. It operates in the United States, Australia, New Zealand, Singapore, and South Korea. Cellegy Pharmaceuticals was incorporated in 1989 and is headquartered in Brisbane, California. | | Our Not Available Rating on CLGY was issued on 12/04/2008 |
CELLEGY PHARM INC Technical Rating
|
|
|
|
